U.S., Feb. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07428044) titled 'A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer' on Feb. 17.
Brief Summary: The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab deruxtecan before routine surgery to remove tumors.
Study Start Date: Feb. 13
Study Type: INTERVENTIONAL
Condition:
Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer Stage II
Non-Small Cell Lung Cancer Stage IIIA
Non-Small Cell Lung Cancer Stage IIIB
Intervention:
DRUG: Trastuzumab Deruxtecan
Trastuzumab deruxtecan (T-DXd, f...